[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344130-105":59,"doc-detail-344130-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-novel-glycoengineered-humanized-antibody-targeting-dlk1-exhibits-potent-anti-tumor-activity-in-dlk1-expressing-liver-cancer-cell-xenograft-models-revised-expanded","A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models - Revised - Expanded","","Delta-like 1 homolog (DLK1), a non-canonical Notch ligand, is highly expressed across malignant tumors, with marked enrichment in hepatocellular carcinoma (HCC). CBA-1205 is an afucosylated humanized anti-DLK1 antibody engineered to enhance antibody-dependent cellular cytotoxicity (ADCC). Binding was characterized by ELISA and flow cytometry, ADCC was measured with human peripheral blood mononuclear cells, and antitumor effects were tested in DLK1-expressing liver cancer xenograft models. Toxicity and toxicokinetics were evaluated in cynomolgus monkeys. CBA-1205 selectively bound DLK1 and showed favorable safety with long-lasting tumor regression as monotherapy and with lenvatinib, supporting clinical potential in HCC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-novel-glycoengineered-humanized-antibody-targeting-dlk1-exhibits-potent-anti-tumor-activity-in-dlk1-expressing-liver-cancer-cell-xenograft-models-revised-expanded/344130/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-novel-glycoengineered-humanized-antibody-targeting-dlk1-exhibits-potent-anti-tumor-activity-in-dlk1-expressing-liver-cancer-cell-xenograft-models-revised-expanded/344130.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is DLK1 and why is it relevant to hepatocellular carcinoma?","Question",{"text":112,"@type":113},"DLK1 is a non-canonical Notch ligand highly expressed in malignant tumors, especially HCC. Its expression makes it a potential therapeutic target.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the binding and ADCC activity of CBA-1205 evaluated?",{"text":117,"@type":113},"CBA-1205 binding was analyzed using ELISA and fluorescence-activated cell sorting assays. ADCC activity was assessed using human peripheral blood mononuclear cells as effector cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports CBA-1205 antitumor efficacy and safety?",{"text":121,"@type":113},"Antitumor efficacy was tested in DLK1-expressing liver cancer xenograft mouse models, while toxicity and toxicokinetic profiles were evaluated in cynomolgus monkeys. The results indicated favorable safety and long-lasting efficacy with tumor regression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344130,1791219224,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Article  \nA Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models †  \nKoji Nakamura *, Kota Takahashi, Izumi Sakaguchi‡, Takumi Satoh, Lingyi Zhang§ , Hiroyuki Yanai and Yukihito Tsukumo *  \nCitation: Nakamura, K.; Takahashi, K.; Sakaguchi, I.; Satoh, T.; Zhang, L.; Yanai, H.; Tsukumo, Y. A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models. Int. J. Mol. Sci. 2024, 25, 13627. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms252413627](10.3390/ijms252413627)  \nAcademic Editor: Moon Jong Kim  \nReceived: 23 October 2024  \nRevised: 13 December 2024  \nAccepted: 17 December 2024  \nPublished: 19 December 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nChiome Bioscience Inc., 3-12-1 Honmachi, Shibuya-ku, Tokyo 151-0071, Japan; [ktakahashi@chiome.co.jp](ktakahashi@chiome.co.jp) (K.T.);  \n[i.sakaguchi@renatherapeutics.com](i.sakaguchi@renatherapeutics.com) (I.S.); [tsato@chiome.co.jp](tsato@chiome.co.jp) (T.S.); [lingyi.zhang2@pfizer.com](lingyi.zhang2@pfizer.com) (L.Z.);  \n[hyanai@chiome.co.jp](hyanai@chiome.co.jp) (H.Y.)  \n* Correspondence: [knakamura@chiome.co.jp](knakamura@chiome.co.jp) (K.N.); [ytsukumo@chiome.co.jp](ytsukumo@chiome.co.jp) (Y.T.)  \n† This article is a revised and expanded version of a papers entitled “CBA-1205, a novel glycoengineered humanized antibody targeting DLK-1 exhibits potent anti-tumor activity in DLK-1 expressing tumor xenograft models” and “ Synergistic and long-lasing anti-tumor efficacy of CBA-1205, a novel glycoengineered humanized antibody targeting DLK-1, in combination with Lenvatinib in human HCC xenograft models”, which were presented AACR Annual Meeting 2019, Atlanta, GA, USA, 29 March–3 April 2019, AACR Annual Meeting 2023, Orland, FL, USA, 14–19 April 2023 .  \n‡ Current address: Rena Therapeutics Inc., Shonan Health Innovation Park, 26-1, Muraokahigashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan.  \n§ Current address: Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan.  \nAbstract: Delta-like 1 homolog (DLK1), a non-canonical Notch ligand, is highly expressed in various malignant tumors, especially in hepatocellular carcinoma (HCC) . CBA-1205 is an afucosylated humanized antibody against DLK1 with enhanced antibody-dependent cellular cytotoxicity (ADCC) . The binding characteristics of CBA-1205 were analyzed by enzyme-linked immunosorbent assay and fluorescence-activated cell sorting assay. The ADCC activity of CBA-1205 was assessed. The antitumor efficacy of CBA-1205 was evaluated in xenograft mouse models, and toxicity and toxicokinetic profiles of CBA-1205 were evaluated in cynomolgus monkeys. CBA-1205 selectively bound to DLK1 among the Notch ligands and only to monkey and human DLK1 . The binding epitope was between epidermal growth factor-like domains 1 and 2 of DLK1, which are not involved in any known physiological functions. The ADCC activity of CBA-1205 was confirmed using human peripheral blood mononuclear cells as effector cells. CBA-1205 as a single agent and in combination with lenvatinib demonstrated long-lasting anti-tumor efficacy, including tumor regression, in two liver cancer xenograft models. The toxicity and toxicokinetic profiles of CBA-1205 in cynomolgus monkeys were favorable. These findings suggest that CBA-1205 has the potential to be a useful therapeutic option for drug treatment in HCC. A phase 1 study is ongoing in patients with advanced cancers (jRCT2080225288, NCT06636435) .  \nKeywords: Delta-like 1 homolog; CBA-1205; antibody-","cbCaihlGSyxw9BJ2","https://ap.wps.com/l/cbCaihlGSyxw9BJ2","pdf",3351460,17,"English","# Abstract\n# Introduction\n## Background on liver cancer and HCC treatments\n## Role of intratumor heterogeneity and cancer stem cells\n## DLK1 as a therapeutic target","[{\"question\":\"What is DLK1 and why is it relevant to hepatocellular carcinoma?\",\"answer\":\"DLK1 is a non-canonical Notch ligand highly expressed in malignant tumors, especially HCC. Its expression makes it a potential therapeutic target.\"},{\"question\":\"How was the binding and ADCC activity of CBA-1205 evaluated?\",\"answer\":\"CBA-1205 binding was analyzed using ELISA and fluorescence-activated cell sorting assays. ADCC activity was assessed using human peripheral blood mononuclear cells as effector cells.\"},{\"question\":\"What evidence supports CBA-1205 antitumor efficacy and safety?\",\"answer\":\"Antitumor efficacy was tested in DLK1-expressing liver cancer xenograft mouse models, while toxicity and toxicokinetic profiles were evaluated in cynomolgus monkeys. The results indicated favorable safety and long-lasting efficacy with tumor regression.\"}]","A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models - Revised - Expanded | PDF",1790053087,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d478731cb5321458ab8b26d8888bc7b7.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b42584444c8cc0a637a6b3e9e1569637.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f674f5a39556866f9d5c0e8149f1c9ec.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34a6d5ea7c11d3a10f3eaab675852d9d.webp",980,1385]